We are live on ! Find out more
ALXN

Alexion Pharmaceuticals
ALXN

Delisted

ALXN was delisted on the 20th of July, 2021.

Back to rankings

595 hedge funds and large institutions have $30B invested in Alexion Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 88 funds opening new positions, 218 increasing their positions, 214 reducing their positions, and 45 closing their positions.

New
Increased
Maintained
Reduced
Closed

96% more first-time investments, than exits

New positions opened: 88 | Existing positions closed: 45

27% more call options, than puts

Call options by funds: $551M | Put options by funds: $435M

15% more capital invested

Capital invested by funds: $26B → $30B (+$4.01B)

6% more funds holding

Funds holding: 559 → 595 (+36)

2% more repeat investments, than reductions

Existing positions increased: 218 | Existing positions reduced: 214

0% more funds holding in top 10

Funds holding in top 10: 19 → 19 (0)

Holders
595
Holders Change
+36
Holders Change %
+6.44%
% of All Funds
14.83%
Holding in Top 10
19
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.47%
New
88
Increased
218
Reduced
214
Closed
45
Calls
$551M
Puts
$435M
Net Calls
+$117M
Net Calls Change
-$98.3M

Top Buyers

1
Jennison Associates
Jennison Associates
New York
+$636M
2
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$118M
3
AQR Capital Management
AQR Capital Management
Connecticut
+$83.6M
4
UBS AM
UBS AM
Illinois
+$69.1M
5
Alkeon Capital Management
Alkeon Capital Management
New York
+$67.9M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$328M
2
Sands Capital Management
Sands Capital Management
Virginia
-$213M
3
Goldman Sachs
Goldman Sachs
New York
-$183M
4
State Street
State Street
Massachusetts
-$82.3M
5
BlackRock
BlackRock
New York
-$77.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
IGIM
251
I.G. Investment Management
Manitoba, Canada
$3.93M – – –
CIBC Asset Management
252
CIBC Asset Management
Ontario, Canada
$3.9M +$34.9K +257 +0.9%
KBC Group
253
KBC Group
Belgium
$3.78M -$410K -3,018 -10%
MOACM
254
Mutual of America Capital Management
New York
$3.76M -$89.1K -656 -2%
Cerity Partners
255
Cerity Partners
New York
$3.75M +$2.73M +20,084 +301%
AB
256
Amalgamated Bank
New York
$3.66M +$70.4K +518 +2%
B
257
BP
United Kingdom
$3.65M – – –
UFF
258
USA Financial Formulas
Michigan
$3.63M +$3.52M +25,886 New
Baird Financial Group
259
Baird Financial Group
Wisconsin
$3.59M +$167K +1,228 +5%
SSA
260
Schonfeld Strategic Advisors
New York
$3.57M +$1.48M +10,897 +75%
LPL Financial
261
LPL Financial
California
$3.53M +$1.35M +9,927 +65%
AGA
262
Altrinsic Global Advisors
Connecticut
$3.51M -$679K -5,000 -17%
CG
263
Cutler Group
California
$3.38M -$8.85M -65,177 -73%
PVI
264
Pura Vida Investments
New York
$3.35M -$8.72M -64,212 -73%
OPERF
265
Oregon Public Employees Retirement Fund
Oregon
$3.33M +$17.5K +129 +0.5%
AP
266
Archon Partners
New Jersey
$3.24M +$3.14M +23,100 New
CSS
267
Cubist Systematic Strategies
Connecticut
$3.21M +$1.74M +12,805 +127%
DnB Asset Management
268
DnB Asset Management
Norway
$3.2M – – –
PPCM
269
Pillar Pacific Capital Management
California
$3.2M +$213K +1,565 +7%
SAM
270
Securian Asset Management
Minnesota
$3.19M +$20.7K +152 +0.7%
LCM
271
Laurion Capital Management
New York
$3.18M +$3.08M +22,698 New
Twin Tree Management
272
Twin Tree Management
Texas
$3.17M +$3.07M +22,622 New
SAM
273
Shell Asset Management
Netherlands
$3.16M -$480K -3,535 -14%
Susquehanna International Group
274
Susquehanna International Group
Pennsylvania
$3.12M -$50.7M -372,967 -94%
OAM
275
Oppenheimer Asset Management
New York
$3.11M +$131K +965 +5%
9 10
11
12 13

ALXN Hedge Fund Activity: Q3 2017 in Review

595 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q3 2017, worth a combined $30B — up 15% from $26B a quarter earlier.

Buyers outnumbered sellers: 88 funds opened new ALXN positions and 45 closed out — a net gain of 43 holders — while 218 added to existing stakes and 214 trimmed.

The largest buyer was Jennison Associates, adding an estimated $636M. The largest seller was Fidelity Investments, cutting an estimated $328M.

  • 595 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q3 2017, up from 559 in Q2 2017.
  • Funds reported $30B of Alexion Pharmaceuticals stock for Q3 2017, up 15% quarter-over-quarter.
  • 88 funds opened new Alexion Pharmaceuticals positions in Q3 2017 and 45 closed out, a net change of +43 holders.
  • The largest Alexion Pharmaceuticals buyer in Q3 2017 was Jennison Associates, an estimated $636M added.
  • The largest Alexion Pharmaceuticals seller in Q3 2017 was Fidelity Investments, an estimated $328M sold.

Based on aggregated 13F filings for Q3 2017.